Kyorin, Teijin Mull Limited Partnership To Develop Respiratory Products
This article was originally published in PharmAsia News
Kyorin Holdings and Teijin are considering a partnership to combine their skills in developing treatments for respiratory diseases, matching Teijin's medical equipment with Kyorin's drugs.
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.